Recursion Pharmaceuticals (NASDAQ:RXRX) Price Target Lowered to $10.00 at KeyCorp

Recursion Pharmaceuticals (NASDAQ:RXRX) had its target price decreased by KeyCorp from $12.00 to $10.00 in a report published on Wednesday,Benzinga reports. KeyCorp currently has an overweight rating on the stock.

Separately, Needham & Company LLC reaffirmed a “buy” rating and set a $11.00 price objective on shares of Recursion Pharmaceuticals in a research note on Wednesday, December 11th. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $8.75.

Recursion Pharmaceuticals Price Performance

NASDAQ:RXRX opened at $6.88 on Wednesday. The stock has a 50 day moving average of $6.94 and a two-hundred day moving average of $7.01. Recursion Pharmaceuticals has a 12 month low of $5.60 and a 12 month high of $15.74. The firm has a market cap of $2.69 billion, a P/E ratio of -4.50 and a beta of 0.85. The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.01). Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The firm had revenue of $26.08 million during the quarter, compared to analyst estimates of $12.62 million. During the same period in the prior year, the company posted ($0.43) earnings per share. The firm’s revenue for the quarter was up 147.6% compared to the same quarter last year. On average, analysts expect that Recursion Pharmaceuticals will post -1.57 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CFO Michael Secora sold 15,000 shares of the stock in a transaction that occurred on Wednesday, November 13th. The shares were sold at an average price of $7.66, for a total value of $114,900.00. Following the completion of the sale, the chief financial officer now owns 1,499,631 shares of the company’s stock, valued at $11,487,173.46. This represents a 0.99 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $6.67, for a total transaction of $76,351.49. Following the sale, the director now directly owns 7,089,007 shares in the company, valued at approximately $47,283,676.69. The trade was a 0.16 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 55,341 shares of company stock worth $393,490. Insiders own 15.75% of the company’s stock.

Hedge Funds Weigh In On Recursion Pharmaceuticals

Large investors have recently modified their holdings of the business. Allspring Global Investments Holdings LLC purchased a new stake in Recursion Pharmaceuticals in the 3rd quarter valued at about $25,000. GAMMA Investing LLC increased its position in shares of Recursion Pharmaceuticals by 1,979.2% during the fourth quarter. GAMMA Investing LLC now owns 5,198 shares of the company’s stock valued at $35,000 after acquiring an additional 4,948 shares during the last quarter. Farther Finance Advisors LLC lifted its holdings in shares of Recursion Pharmaceuticals by 176.9% in the 3rd quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company’s stock worth $42,000 after acquiring an additional 4,091 shares during the last quarter. KBC Group NV boosted its position in shares of Recursion Pharmaceuticals by 79.9% during the 3rd quarter. KBC Group NV now owns 7,602 shares of the company’s stock worth $50,000 after purchasing an additional 3,377 shares during the period. Finally, Amalgamated Bank increased its holdings in Recursion Pharmaceuticals by 52.4% in the 2nd quarter. Amalgamated Bank now owns 7,152 shares of the company’s stock valued at $54,000 after purchasing an additional 2,459 shares during the last quarter. Institutional investors and hedge funds own 89.06% of the company’s stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.